Anatara Lifesciences Limited (ASX:ANR) CEO, Steven Lydeamore presents on the company's lead Gastrointestinal Reprogramming Product (GaRP) for Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD) and its clinical studies program at FNN's Investor Event.
- Market capitalisation of $24.4 million
- Key appointments with significant human health experience including Sue MacLeman, Dr Jane Ryan, Dr David Brookes and Steve Lydeamore
- Developed "Detach" - a natural, safe, non-antibiotic product that aids in the control of diarrhoea in livestock. It is Australian Pesticides and Veterinary Medicines Authority approved for use in piglets.
- Successful Proof of Concept Studies for GaRP formulation which reduces inflammation by up to 85%
For more, watch CEO Steven Lydeamore present.